---
type: Condition
title: Anxiety Disorders
description: Anxiety disorders (GAD, social anxiety, panic disorder, phobias) as evaluated and treated by CARMAhealth with medication management, TMS, and ketamine therapy.
resource: https://carmahealth.com/conditions/anxiety
tags: [carmahealth, condition, anxiety, gad, panic-disorder, psychiatry]
timestamp: 2026-07-08T20:00:00Z
---

# Anxiety Disorders

Condition profile within the [CARMAhealth](../carmahealth.md) bundle. Facts below are drawn from the provider's own condition page, retrieved 2026-07-08.

## How CARMAhealth describes it

CARMAhealth frames anxiety disorders as real medical conditions rooted in brain chemistry, not personal shortcomings, presenting variably as constant dread, panic attacks, avoidance of social situations, or physical symptoms (racing heartbeat, muscle tension, chest tightness, sleep disruption). The types named are generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, and specific phobias.

The provider notes anxiety commonly co-occurs with [depression](./depression.md) and [insomnia](./insomnia.md), and that evaluation screens for these and rules out medical causes.

## Screening / evaluation approach

Treatment begins with a [psychiatric evaluation](../services/psychiatric-evaluation.md) to identify the specific anxiety disorder, rule out medical causes, and assess co-occurring conditions; the site advises evaluation when anxiety persists more than a few weeks, interferes with work or relationships, causes physical symptoms, or does not respond to self-care.

## Treatment options offered

- [Medication management](../services/medication-management.md) — SSRIs described as first-line for most anxiety disorders; SNRIs, buspirone, and in certain cases short-term benzodiazepines also cited.
- [TMS therapy](../services/tms-therapy.md) — for anxiety occurring alongside depression or not responding to medication alone.
- [Ketamine therapy](../services/ketamine-therapy.md) — described as a rapid-acting option when anxiety accompanies treatment-resistant depression or has not responded to standard medication.

## Claims noted (attributed)

- The site states, citing NIMH, that an estimated 19.1% of U.S. adults experienced an anxiety disorder in the past year and 31.1% will in their lifetime, with women nearly twice as likely to be affected (23.4% vs. 14.3% past-year prevalence).
- The site states, citing the Anxiety and Depression Association of America, that only about 36.9% of those affected receive treatment.
- The site states TMS is FDA-cleared for depression with comorbid anxiety symptoms, that research shows significant anxiety reductions when TMS targets regions involved in mood and worry regulation, that insurance typically covers TMS when anxiety is treated alongside depression, and that TMS for anxiety alone is self-pay.
- The site states most insurance plans cover psychiatric evaluation and medication management for anxiety; TMS coverage varies by plan and typically requires documentation of prior medication trials.
- The site states every anxiety treatment plan is designed and supervised by a board-certified psychiatrist or psychiatric nurse practitioner.

## Sources

- Live page: https://carmahealth.com/conditions/anxiety — Retrieved 2026-07-08.
- Mirror: https://mr.carmahealth.com/conditions/anxiety — Retrieved 2026-07-08.